phase I clinical study Sep 14, 2022 FDA Clears Anbogen Therapeutics to Study ABT-101 in HER2-Mutant NSCLC Patients in the US Sep 13, 2022 Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 6, 2022 Monte Rosa to Begin Phase I/II Trial of MRT-2359 in MYC-Driven Solid Cancers Sep 6, 2022 Ideaya Begins Phase I Trial of Darovasertib in Primary Uveal Melanoma Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 25, 2022 Byondis Begins Phase I Trial of BYON3521 in Solid Tumors Aug 24, 2022 MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape Premium Aug 23, 2022 K36 Therapeutics Gets FDA Clearance to Start Phase I Trial of Multiple Myeloma Candidate Aug 22, 2022 IDRx Launches With Back-to-the-Future Combination Drug Development Strategy Premium Aug 22, 2022 Kronos Begins Trial of Second SYK Inhibitor in FLT3-Mutated AML Aug 22, 2022 Cue Biopharma Doses First Patient in Phase I Trial of CUE-102 in WT1-Expressing Tumors Aug 19, 2022 Sirnaomics Launches Phase I/II Trial of RNAi Therapeutic for Facial Skin Cancer Lesions Aug 19, 2022 Verismo Therapeutics Files IND to Study Cell Therapy in Advanced Mesothelin-Expressing Solid Tumors Aug 18, 2022 Innovative Cellular Therapies Begins Trial of Autologous CAR T-Cell Therapy in Colorectal Cancer Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Aug 16, 2022 GSK Waives Rights to Ideaya's MAT2A Inhibitor IDE397 Aug 15, 2022 Anixa Biosciences Doses First Ovarian Cancer Patient in Novel Autologous Cell Therapy Trial Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Aug 4, 2022 Valo Therapeutics Advancing Plans for Oncolytic Virus Treatments With Tailored Immunogenic Peptides Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
